Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Cancer research - 15 Feb 2008

Amornphimoltham Panomwat, Patel Vyomesh, Leelahavanichkul Kantima, Abraham Robert T, Gutkind J Silvio

Abstract excerpt

Emerging evidence supporting the activation of the Akt-mammalian target of rapamycin (mTOR) signaling network in head and neck squamous cell carcinoma (HNSCC) progression has provided the rationale for exploring the therapeutic potential of inhibiting this pathway for HNSCC treatment. Indeed, rapamycin, a clinically relevant mTOR inhibitor, promotes the rapid regression of HNSCC-tumor xenografts in mice. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Cell Growth Processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endothelial Cells

Share to Head and Neck Neoplasms

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 18281490
DOI: 10.1158/0008-5472.CAN-07-1756
PMCID: PMC3443567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.PMID 18281490Read ↗

Mechanisms of resistance to rapamycins.Semantic proximity Read ↗

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialSemantic proximity Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR InhibitorSemantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Semantic proximity Read ↗

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.Semantic proximity Read ↗

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Semantic proximity Read ↗

Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.Semantic proximity Read ↗

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell LinesSemantic proximity Read ↗

Unconventional mechanism of action and resistance to rapalogs in renal cancer.Semantic proximity Read ↗

Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.